118 related articles for article (PubMed ID: 29990556)
1. Conformational and dynamical basis for cross-reactivity observed between anti HIV-1 protease antibody with protease and an epitope peptide from it.
Badaya A; Sasidhar YU
Int J Biol Macromol; 2018 Oct; 118(Pt B):1696-1707. PubMed ID: 29990556
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of a cross-reaction complex between an anti-HIV-1 protease antibody and an HIV-2 protease peptide.
Rezacova P; Brynda J; Lescar J; Fabry M; Horejsi M; Sieglova I; Sedlacek J; Bentley GA
J Struct Biol; 2005 Mar; 149(3):332-7. PubMed ID: 15721587
[TBL] [Abstract][Full Text] [Related]
3. Limited conformational flexibility in the paratope may be responsible for degenerate specificity of HIV epitope recognition.
Bhowmick A; Salunke DM
Int Immunol; 2013 Feb; 25(2):77-90. PubMed ID: 22968994
[TBL] [Abstract][Full Text] [Related]
4. Conformational dynamics of a short antigenic peptide in its free and antibody bound forms gives insight into the role of β-turns in peptide immunogenicity.
Shukla RT; Sasidhar YU
Proteins; 2015 Jul; 83(7):1352-67. PubMed ID: 26033223
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations.
Badaya A; Sasidhar YU
Sci Rep; 2020 Mar; 10(1):5501. PubMed ID: 32218488
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.
Cardoso RM; Brunel FM; Ferguson S; Zwick M; Burton DR; Dawson PE; Wilson IA
J Mol Biol; 2007 Feb; 365(5):1533-44. PubMed ID: 17125793
[TBL] [Abstract][Full Text] [Related]
7. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
8. Preliminary crystallographic studies of an anti-HIV-1 protease antibody that inhibits enzyme activity.
Lescar J; Stouracova R; Riottot MM; Chitarra V; Brynda J; Fabry M; Horejsi M; Sedlacek J; Bentley GA
Protein Sci; 1996 May; 5(5):966-8. PubMed ID: 8732768
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional structure of an Fab-peptide complex: structural basis of HIV-1 protease inhibition by a monoclonal antibody.
Lescar J; Stouracova R; Riottot MM; Chitarra V; Brynda J; Fabry M; Horejsi M; Sedlacek J; Bentley GA
J Mol Biol; 1997 Apr; 267(5):1207-22. PubMed ID: 9150407
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody.
Rezacova P; Lescar J; Brynda J; Fabry M; Horejsi M; Sedlacek J; Bentley GA
Structure; 2001 Oct; 9(10):887-95. PubMed ID: 11591344
[TBL] [Abstract][Full Text] [Related]
11. The role of structure in antibody cross-reactivity between peptides and folded proteins.
Craig L; Sanschagrin PC; Rozek A; Lackie S; Kuhn LA; Scott JK
J Mol Biol; 1998 Aug; 281(1):183-201. PubMed ID: 9680484
[TBL] [Abstract][Full Text] [Related]
12. Cross-reactive binding of cyclic peptides to an anti-TGFalpha antibody Fab fragment: an X-ray structural and thermodynamic analysis.
Hahn M; Winkler D; Welfle K; Misselwitz R; Welfle H; Wessner H; Zahn G; Scholz C; Seifert M; Harkins R; Schneider-Mergener J; Höhne W
J Mol Biol; 2001 Nov; 314(2):293-309. PubMed ID: 11718562
[TBL] [Abstract][Full Text] [Related]
13. Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.
Liang Y; Guttman M; Davenport TM; Hu SL; Lee KK
Biochemistry; 2016 Apr; 55(15):2197-213. PubMed ID: 27003615
[TBL] [Abstract][Full Text] [Related]
14. Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia.
Shi X; Zheng J; Yan T
J Mol Model; 2018 Mar; 24(4):79. PubMed ID: 29500665
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIV protease by monoclonal antibodies.
Rezacova P; Brynda J; Fabry M; Horejsi M; Stouracova R; Lescar J; Chitarra V; Riottot MM; Sedlacek J; Bentley GA
J Mol Recognit; 2002; 15(5):272-6. PubMed ID: 12447903
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
[TBL] [Abstract][Full Text] [Related]
17. Structural Analysis of Der p 1-Antibody Complexes and Comparison with Complexes of Proteins or Peptides with Monoclonal Antibodies.
Osinski T; Pomés A; Majorek KA; Glesner J; Offermann LR; Vailes LD; Chapman MD; Minor W; Chruszcz M
J Immunol; 2015 Jul; 195(1):307-16. PubMed ID: 26026055
[TBL] [Abstract][Full Text] [Related]
18. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
19. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
20. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
